[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-337639-105":3,"detail-sidebar-cat-0-en-105":85,"doc-detail-337639-en":134},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":78,"head_meta":80,"extra_data":82,"updated_unix":84},105,"en","serum-ny-eso-1-antibody-as-a-predictive-biomarker-for-postoperative-recurrence-of-gastric-cancer-a-multicenter-prospective-observational-study","Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer - a multicenter prospective observational study","","Serum NY-ESO-1 antibody responses are evaluated as a predictive biomarker for postoperative recurrence in resectable cT3-4 gastric cancer through a multicenter prospective observational study conducted from 2012 to 2021. NY-ESO-1 and p53 antibody responses were serially measured every 3 months for 1 year in patients with positive preoperative antibody responses, with recurrence defined by positivity at 3 and 12 months. Among 1001 patients, NY-ESO-1 turned negative in non-recurrent patients but stayed positive in recurrent patients. Multivariate analysis identified NY-ESO-1 positivity at 3 and 12 months as independent prognostic factors for shorter recurrence-free intervals.",{"@graph":14,"@context":77},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/serum-ny-eso-1-antibody-as-a-predictive-biomarker-for-postoperative-recurrence-of-gastric-cancer-a-multicenter-prospective-observational-study/337639/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/serum-ny-eso-1-antibody-as-a-predictive-biomarker-for-postoperative-recurrence-of-gastric-cancer-a-multicenter-prospective-observational-study/337639.png","ImageObject",300,407,{"name":42,"@type":43},"Ava Thompson","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-21",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",7,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69,73],{"name":60,"@type":61,"acceptedAnswer":62},"What is the study trying to predict in gastric cancer patients after surgery?","Question",{"text":63,"@type":64},"The study investigates whether serum NY-ESO-1 antibody responses can predict postoperative recurrence in resectable cT3-4 gastric cancer.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were NY-ESO-1 and p53 antibody responses measured over time?",{"text":68,"@type":64},"Patients with positive preoperative antibody responses had postoperative NY-ESO-1 and p53 antibody responses evaluated serially every 3 months for 1 year.",{"name":70,"@type":61,"acceptedAnswer":71},"What did the results show about NY-ESO-1 antibody behavior in recurrent versus non-recurrent patients?",{"text":72,"@type":64},"NY-ESO-1 antibody responses became negative after surgery in non-recurrent patients but remained positive in recurrent patients, with different negativity rates at 3 and 12 months.",{"name":74,"@type":61,"acceptedAnswer":75},"Did NY-ESO-1 positivity remain significant after adjusting for other factors?",{"text":76,"@type":64},"Yes. Multivariate analysis found NY-ESO-1 antibody positivity at 3 months and 12 months as independent prognostic factors for a shorter recurrence-free interval.","https://schema.org",{"og:url":32,"og:type":79,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":81,"canonical":32},"index,follow",{"doc_id":83,"site_id":7},337639,1790185682,{"code":4,"msg":86,"data":87},"success",[88,92,96,100,105,110,114,118,123,126,130],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":97,"show_sort_weight":98,"slug":99},"Exam",70,"exam",{"id":101,"doc_module":4,"doc_module_name":25,"category_name":102,"show_sort_weight":103,"slug":104},5,"Comic",60,"comic",{"id":106,"doc_module":4,"doc_module_name":25,"category_name":107,"show_sort_weight":108,"slug":109},6,"Technology",50,"technology",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":111,"show_sort_weight":112,"slug":113},"Healthcare",40,"healthcare",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":116,"slug":117},8,30,"research-report",{"id":119,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":121,"slug":122},9,"Religion & Spirituality",20,"religion-spirituality",{"id":121,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":121,"slug":125},"World Cup","world-cup",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":127,"slug":129},10,"Lifestyle","lifestyle",{"id":131,"doc_module":4,"doc_module_name":25,"category_name":132,"show_sort_weight":101,"slug":133},19,"General","general",{"code":4,"msg":86,"data":135},{"doc_id":83,"user_id":136,"nickname":42,"user_avatar":137,"doc_module":4,"category_id":115,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":138,"file_id":139,"file_url":140,"file_type":141,"file_size":142,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":119,"language":143,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":144,"faqs":145,"seo_title":146,"seo_description":12,"update_tm":147,"read_time":148,"preview_page_count":33,"preview_urls":149},1649267921044,"https://us-avatar.wpscdn.com/avatar/1800007509477c92dfb?_k=1786009248482753345","British Journal of Cancer [www.nature.com/bjc](www.nature.com/bjc)  \nARTICLE  \nClinical Studies  \nOPEN  \nSerum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer: a multicenter prospective observational study  \nTakuro Saito 1 ✉, Yukinori Kurokawa 1, Kazumasa Fujitani2, Ryohei Kawabata3, Atsushi Takeno4, Jota Mikami5, Shunji Endo6, Jin Matsuyama7, Yusuke Akamaru8, Masashi Hirota9, Kentaro Kishi10, Shinya Urakawa1, Kei Yamamoto 1, Koji Tanaka 1, Tsuyoshi Takahashi 1, Mikio Oka11, Hisashi Wada 12, Hidetoshi Eguchi1 and Yuichiro Doki1  \n© The Author(s), 2024  \n\n|  | BACKGROUND: No reliable marker has been identiﬁed to predict postoperative recurrence of gastric cancer. We designed a clinical trial to investigate the utility of serum NY-ESO-1 antibody responses as a predictive marker for postoperative recurrence in gastric cancer.\u003Cbr>METHODS: A multicenter prospective study was conducted between 2012 and 2021 . Patients with resectable cT3-4 gastric cancer were included. Postoperative NY-ESO-1 and p53 antibody responses were serially evaluated every 3 months for 1 year in patients with positive preoperative antibody responses. The recurrence rate was assessed by the positivity of antibody responses at 3 and 12 months postoperatively.\u003Cbr>RESULTS: Among 1001 patients, preoperative NY-ESO-1 and p53 antibody responses were positive in 12.6% and 18.1% of patients, respectively. NY-ESO-1 antibody responses became negative postoperatively in non-recurrent patients (negativity rates; 45% and 78% at 3 and 12 months, respectively), but remained positive in recurrent patients (negativity rates; 9% and 8%, respectively) . p53 antibody responses remained positive in non-recurrent patients. In multivariate analysis, NY-ESO-1 antibody positivity at 3 months (P \u003C 0.03) and 12 months (P \u003C 0.001) were independent prognostic factors for a shorter recurrence-free interval.\u003Cbr>CONCLUSIONS: Serum NY-ESO-1 antibodies may be a useful predictive marker for postoperative recurrence in gastric cancer |  |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n| .\u003Cbr>CLINICAL TRIAL REGISTRATION: UMIN000007925 . |  |  |\n|  | British Journal of Cancer (2024) 130:1157–1165; [https://doi.org/10.1038/s41416-023-02540-3](https://doi.org/10.1038/s41416-023-02540-3) |  |\n|  |  |  |\n\nINTRODUCTION  \nGastric cancer is the fourth leading cause of cancer-related death worldwide [1] . Advanced gastric cancer has a high recurrence rate even after curative surgery, leading to a poor prognosis overall. Early prediction of postoperative recurrence is important to determine the indication for intensive adjuvant chemotherapy and to improve treatment outcomes of advanced gastric cancer [2–4] . Although several methods have been developed to predict postoperative recurrence, no reliable predictive marker has been identiﬁed [5–9] . Carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA19-9) are common tumor markers for gastric cancer in Japan, but these serum markers are positive in only 20–60% of cases and can predict recurrence approximately 3 months before image-based evidence of recurrence [10–12] .  \nNY-ESO-1 antigen is one of the cancer-testis antigens initially identiﬁed by the serological analysis of recombinant cDNA expression libraries and is expressed in the normal testis, placenta, and tumor tissues [13] . They are highly tumor-speciﬁc and immunogenic and frequently induce speciﬁc immune responses [14, 15] . Spontaneous NY-ESO-1 antibody responses were observed in 9.7–11.1% of gastric cancers, 3.9–29.4% of esophageal cancers, 9.4% of melanomas, and 9–23% of lung cancers, but these responses were not detected in non-cancerous donors [16–19] . Therefore, NY-ESO-1 humoral immune responses may be used as a serological marker to detect these cancers. In our previous cohort study of gastric cancer, serum NY-ESO-1 antibody responses","cbCaivx3ldQZl8EK","https://ap.wps.com/l/cbCaivx3ldQZl8EK","pdf",774920,"English","# Background\n# Methods\n# Results\n# Conclusions\n# Introduction\n## Clinical context and need for predictive markers\n## Rationale for NY-ESO-1 and p53 antibodies\n# Clinical trial registration\n# Publication information","[{\"question\":\"What is the study trying to predict in gastric cancer patients after surgery?\",\"answer\":\"The study investigates whether serum NY-ESO-1 antibody responses can predict postoperative recurrence in resectable cT3-4 gastric cancer.\"},{\"question\":\"How were NY-ESO-1 and p53 antibody responses measured over time?\",\"answer\":\"Patients with positive preoperative antibody responses had postoperative NY-ESO-1 and p53 antibody responses evaluated serially every 3 months for 1 year.\"},{\"question\":\"What did the results show about NY-ESO-1 antibody behavior in recurrent versus non-recurrent patients?\",\"answer\":\"NY-ESO-1 antibody responses became negative after surgery in non-recurrent patients but remained positive in recurrent patients, with different negativity rates at 3 and 12 months.\"},{\"question\":\"Did NY-ESO-1 positivity remain significant after adjusting for other factors?\",\"answer\":\"Yes. Multivariate analysis found NY-ESO-1 antibody positivity at 3 months and 12 months as independent prognostic factors for a shorter recurrence-free interval.\"}]","Serum NY-ESO-1 antibody as a predictive biomarker for postoperative recurrence of gastric cancer - a multicenter prospective observational study | PDF",1790019953,23,[150,154,158,162],{"page_no":22,"url":151,"width":152,"height":153},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b2c5ebe300e3cc754507e0160285ae5d.webp",983,1305,{"page_no":26,"url":155,"width":156,"height":157},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b525cfa83fc867c01422e80d363cf62e.webp",982,1304,{"page_no":30,"url":159,"width":160,"height":161},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c315c6c225e1d9adc1961051082a3d8f.webp",981,1303,{"page_no":33,"url":163,"width":164,"height":165},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/aa93fb2b059a794d12af9a72ac663618.webp",980,1301]